Provectus Biopharmaceuticals (PVCT) Shares are Down -8.99%

Provectus Biopharmaceuticals (PVCT) : During the past 4 weeks, traders have been relatively bearish on Provectus Biopharmaceuticals (PVCT), hence the stock is down -21.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.14% relative to the S&P 500. The 4-week change in the price of the stock is -21.71% and the stock has fallen -8.99% in the past 1 week.

The stock has recorded a 20-day Moving Average of 9.95% and the 50-Day Moving Average is 47.73%.The 200 Day SMA reached 70.88%

Provectus

Provectus Biopharmaceuticals (NYSEMKT:PVCT): After opening at $0.098, the stock dipped to an intraday low of $0.0964 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.1015 and the buying power remained strong till the end. The stock closed at $0.0992 for the day, a gain of 2.16% for the day session. The total traded volume was 1,995,930. The stocks close on the previous trading day was $0.0992.

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. All of its prescription drug candidates are in either the pre-clinical or clinical trial stage. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.